SCHEMBL13317458

SCHEMBL13317458

COC(=O)c1c(OC)cc2c(c1C)C(=O)c1c(O)cccc1C2=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC37A4 O43826 7/20 0.58
ITGA2 P17301 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 3/20 0.52
TSHR P16473 3/20 0.52
TDP1 Q9NUW8 3/20 0.52
MAPK1 P28482 2/20 0.52
KDM4E B2RXH2 2/20 0.52
CYP3A4 P08684 2/20 0.52
RECQL P46063 2/20 0.52
ELANE P08246 2/20 0.52
USP2 O75604 1/20 0.52
BRCA1 P38398 1/20 0.52
IDO1 P14902 1/20 0.50
PSMB11 A5LHX3 2/20 0.49
PSMA7 O14818 2/20 0.49
PSMB1 P20618 2/20 0.49
PSMA1 P25786 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28549227 0.89 SLC37A4 (0.69) SLC37A4MEN1KMT2AALDH1A1MAPT
Aloesaponarin I SCHEMBL29657074 0.89 ITGA2 (0.57) SLC37A4ITGA2MEN1KMT2AALDH1A1
Aloesaponarin I SCHEMBL13317456 0.89 ITGA2 (0.57) SLC37A4ITGA2MEN1KMT2AALDH1A1
SCHEMBL16225976 0.85 EGFR (0.56) SLC37A4ITGA2MEN1KMT2AELANE
SCHEMBL19452223 0.85 EPHX2 (0.48) SLC37A4ITGA2MEN1KMT2AALDH1A1
SCHEMBL19449184 0.83 ELANE (0.60) SLC37A4ITGA2MEN1KMT2AALDH1A1
SCHEMBL16226021 0.83 JUN (0.65) SLC37A4ITGA2MEN1KMT2AALDH1A1
SCHEMBL3190559 0.82 MEN1 (0.58) SLC37A4MEN1KMT2AALDH1A1MAPT
SCHEMBL8976464 0.82 MAPT (0.46) SLC37A4MEN1KMT2AALDH1A1MAPT
SCHEMBL2958068 0.79 ELANE (0.49) SLC37A4MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-11-13 US disclosed
US-7737084-B2 Image fading preventing agent, image forming element, recording medium, image forming method and image CANON KABUSHIKI KAISHA (JP) 2010-06-15 US disclosed
US-7737084-B2 Image fading preventing agent, image forming element, recording medium, image forming method and image CANON KABUSHIKI KAISHA (JP) 2010-06-15 US disclosed
US-20070093386-A1 IMAGE FADING PREVENTING AGENT, IMAGE FORMING ELEMENT, RECORDING MEDIUM, IMAGE FORMING METHOD AND IMAGE CANON KABUSHIKI KAISHA (JP) 2007-04-26 US disclosed
US-20070093386-A1 IMAGE FADING PREVENTING AGENT, IMAGE FORMING ELEMENT, RECORDING MEDIUM, IMAGE FORMING METHOD AND IMAGE CANON KABUSHIKI KAISHA (JP) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER IL2RA, CD74, IL2 SLC37A4 4856/4885ITGA2 793/4885MEN1 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.